Acerus Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Acerus Pharmaceuticals generated cash of -$23,517,000, which is less than the previous year. Cash used in financing activities reached the amount of $16,539,000 last year. Net change in cash is therefore -$6,994,000.
Cash Flow
| 2012 | -23.36M | -159.23K | 17.95M |
|---|---|---|---|
| 2013 | -27.47M | -888.35K | 37.99M |
| 2014 | 8.43M | -41.59M | 48.11M |
| 2015 | -1.02M | -682K | -19.64M |
| 2016 | 3.21M | -71K | -4.47M |
| 2017 | 99K | 10K | -2.43M |
| 2018 | -6.13M | -245K | 7.35M |
| 2019 | -11.38M | -108K | 13.29M |
| 2020 | -22.16M | 0 | 25.46M |
| 2021 | -23.51M | -16K | 16.53M |
ASP.TO Cash Flow Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 9.15M | 5.86M | 3.82M | 3.15M | 5.19M | 6.33M | 31.01M | 18.11M | 9.21M | 14.52M |
Operating activities | ||||||||||
Net income | -33.81M | -24.42M | -16.12M | -18.78M | -8.71M | 11.11M | -9.03M | -22.64M | -31.95M | -28.02M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 681K | 1.01M | 1.11M | 1.95M | 2.04M | 2.20M | 2.40M | 2.56M | 1.16M | 983.69K |
Stock-based compensation expense | 1.09M | 654K | 176K | 449K | 589K | 274K | 584K | 703K | 1.57M | 2.70M |
| Deferred income tax benefit | 1.09M | 654K | 176K | 449K | 589K | 274K | 584K | 703K | 1.57M | 2.70M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 106K | -357K | 986K | 325K | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -2.29M | -819K | 720K | 248K | 641K | -191K | 846K | 2.31M | -1.91M | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -23.51M | -22.16M | -11.38M | -6.13M | 99K | 3.21M | -1.02M | 8.43M | -27.47M | -23.36M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -72K | 0 | -113K | -245K | 0 | -71K | -779K | -282K | -891.57K | -136.94K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -41.41M | 0 | 0 |
Cash generated by investing activities | -16K | 0 | -108K | -245K | 10K | -71K | -682K | -41.59M | -888.35K | -159.23K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 27.82M | 3.35M | 4.37M | 0 | 2M | 0 | 24.87M | 41.52M | 11.73M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -2.52M | -841K | 0 | -6.56M | 0 | -5.78M | 0 | -24.65M | -2.88M | -400.66K |
Cash used in financing activities | 16.53M | 25.46M | 13.29M | 7.35M | -2.43M | -4.47M | -19.64M | 48.11M | 37.99M | 17.95M |
Net Change In Cash | -6.99M | 3.29M | 2.03M | 673K | -2.04M | -1.13M | -24.68M | 12.90M | 8.89M | -5.31M |
Cash at end of period | 2.15M | 9.15M | 5.86M | 3.82M | 3.15M | 5.19M | 6.33M | 31.01M | 18.11M | 9.21M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |